Potassium Channel Ether à go-go1 Is Aberrantly Expressed in Human Liposarcoma and Promotes Tumorigenesis

Abstract EN

The ether à go-go1 (Eag1) channel is overexpressed in a variety of cancers.

However, the expression and function of Eag1 in liposarcoma are poorly understood.

In the present study, the mRNA expression of Eag1 in different adipose tissue samples was examined by real-time PCR.

Then, the protein expression of Eag1 in 131 different adipose tissues from 109 patients was detected by immunohistochemistry.

Next, the associations between Eag1 expression and clinicopathological features of liposarcoma were analyzed.

In addition, the effects of Eag1 on liposarcoma cell proliferation and cycle were evaluated by CCK-8, colony formation, xenograft mouse model, and flow cytometry, respectively.

Finally, the activation of p38 mitogen-activated protein kinase (MAPK) was detected by Western blot analysis to explain the detailed mechanisms of oncogenic potential of Eag1 in liposarcoma.

It was found that Eag1 was aberrantly expressed in over 67% liposarcomas, with a higher frequency than in lipoma, hyperplasia, inflammation, and normal adipose tissues.

However, Eag1 expression was not correlated with clinicopathological features of liposarcoma.

Eag1 inhibitor imipramine or Eag1-shRNA significantly suppressed the proliferation of liposarcoma cells in vitro and in vivo, accompanying with accumulation of cells in the G1 phase.

These results suggest that Eag1 plays an important role in regulating the proliferation and cell cycle of liposarcoma cells and might be a potential therapeutic target for liposarcoma.